hepamet fibrosis score calculator

If you are looking for a quick way to estimate fibrosis risk in metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), this HEPAmet-style fibrosis calculator can help you organize key lab and clinical inputs in one place.

HEPAmet Fibrosis Score (Interactive)

If unknown, ask your clinician/lab. Do not guess for medical decisions.
Important: This tool is for educational screening support and should not replace clinical judgment, elastography, imaging, or biopsy when indicated.

What is the HEPAmet fibrosis score?

The HEPAmet fibrosis score is a non-invasive fibrosis risk model that combines routine patient data (age, blood tests, and metabolic context) to estimate the probability of advanced liver fibrosis. It is commonly discussed alongside other liver fibrosis tools like FIB-4 and NFS, especially in primary care and metabolic liver disease pathways.

How to use this calculator

  • Enter all required values exactly as reported by your lab.
  • Make sure AST and ALT are in U/L and albumin is in g/dL.
  • Use the platelet count unit shown in the form: ×109/L.
  • Click Calculate Score to get a risk estimate.

How results are interpreted

The result is shown from 0 to 1 (and as a percentage). Common practical thresholds used in HEPAmet-oriented workflows are:

  • Low risk: < 0.12
  • Indeterminate risk: 0.12 to 0.46
  • High risk: ≥ 0.47

Low-risk results may support routine follow-up, while indeterminate and high-risk ranges usually need additional evaluation (for example, transient elastography and specialist referral based on local protocol).

Clinical context matters

1) Scores are not diagnosis

Fibrosis calculators are triage tools. They estimate probability, not certainty. Final diagnosis depends on full clinical context, comorbidities, and confirmatory testing.

2) Lab timing affects the result

AST/ALT can fluctuate with illness, alcohol intake, medications, and exercise. A single abnormal value may overestimate risk. Repeat testing is often useful.

3) Use in pathways, not isolation

Most modern care pathways combine non-invasive scores with imaging and risk factor review. This improves sensitivity while reducing unnecessary referrals.

Frequently asked questions

Is this the same as FIB-4?

No. FIB-4 and HEPAmet use different variable sets and different equations. They can complement each other in staged assessment.

Can I use this at home?

You can use it to understand your data, but treatment or diagnosis decisions should always be made with a qualified clinician.

What if my score is high?

Do not panic. A high score means you should arrange medical follow-up promptly for confirmatory testing and management planning.

Method note

This page uses an educational HEPAmet-style logistic model to provide an interpretable fibrosis probability estimate from standard clinical inputs. Exact implementation details can vary by clinical system, pathway, and institutional validation approach.

Displayed probability is calculated as p = 1 / (1 + e-z).

🔗 Related Calculators